Baxter Swings to $294M Q3 Profit, Lifts 2026 Sales and EPS Guidance
BAX sits 65% above its 52-week low of $15.73 on elevated volume (1.9× avg).
Summary
Baxter swung to $294 million of third-quarter net income from a $46 million loss a year ago, with EPS of $0.57 and adjusted EPS of $0.58 on sales of $2.98 billion, up 5% reported and organic. Adjusted EPS fell 16% on a higher effective tax rate. The bigger news is guidance: full-year 2026 adjusted EPS is now $2.05 to $2.15 versus $1.95 to $2.15 before, reported sales growth moves to 4%-5% from 3%-4%, and organic growth to 3%-4% from 2%-3%. Shares were up 2.12% at $26.00 pre-market. This follows the 8-K filed this morning and the earlier Dow Jones report of the same quarter; the raised outlook is the fresh piece. The company has been actively reshaping its balance sheet, upsizing a debt tender to $600 million in August and loosening its net leverage covenant.
At the time of this announcement, BAX was trading at $26.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $13.2B. The 52-week trading range was $15.73 to $30.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: dpa-AFX.